Nipple aspirate fluids from women with breast cancer contain increased levels of group IIa secretory phospholipase A2
- 12 October 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 111 (2), 209-218
- https://doi.org/10.1007/s10549-007-9779-1
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancerBritish Journal of Cancer, 2007
- A feasibility study of the efficacy and tolerability of the combination of Exemestane with the COX-2 inhibitor Celecoxib in post-menopausal patients with advanced breast cancerEuropean Journal of Cancer, 2006
- What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis?International Journal of Cancer, 2006
- Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based TreatmentsClinical Cancer Research, 2004
- Phospholipase A2Prostaglandins, Leukotrienes & Essential Fatty Acids, 2003
- Biological effects of group IIA secreted phosholipase A2FEBS Letters, 2002
- The Role of Cyclooxygenase and Lipoxygenase in Cancer ChemopreventionDrug Metabolism and Drug Interactions, 2000
- Internalization and Degradation of Type IIA Phospholipase A2 in Mast CellsBiochemical and Biophysical Research Communications, 2000
- Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancerSurgery, 1995
- Physiologic, biochemical, and cytologic aspects of nipple aspirate fluidBreast Cancer Research and Treatment, 1986